drugset / Trial / NCT07008469
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NaSingle-groupOpen-labelTreatment
Summary
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Timeline
- Start
- 2025-07-25
- Primary completion
- 2030-08
- Completion
- 2030-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Del-desiran | Unknown | — | Intravenous |